Reata Puts Hopes On Partner Study To Support Bardoxolone Resubmission

 
• By Joseph Haas

Reata says partner Kyowa Kirin’s outcomes study of bardoxolone in chronic kidney disease may address the questions cited by the FDA in its complete response letter for Alport syndrome.

CKD Reata image
CRL is Reata's latest setback in R&D for rare forms of chronic kidney disease • Source: Alamy

More from New Products

More from Scrip